RxDoctor Payments DataLook up a doctor →

Aaron Ritter, MD

Psychiatry · Las Vegas, NVNPI 1154633808

Payments from drug & device makers

$2,658,180in general payments, 2019–2025

Across 385 payments — averaging $6904.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$982K
  • Eisai Inc.$520K
  • Eli Lilly$418K
  • Novartis$277K
  • Genentech, Inc.$266K
  • Lilly USA, LLC$92K
  • plus $104K from 11 others
$19,000in research payments, 2019–2025

Across 4 payments — averaging $4750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$19K

What the payments were for

  • Consulting fees$63,99237%
  • Speaking & faculty fees$95,45255%
  • Travel & lodging$9,1685%
  • Food & beverage$3,9352%
  • Education$270%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,658,180 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$166,375
Medicare patients
585
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate57$307,370
RexultiBrexpiprazole89$118,720
Galantamine ErGalantamine Hbr343$25,174
AdlarityDonepezil Hcl56$24,773
Rivastigmine123$15,156
Memantine Hcl398$13,099
MyrbetriqMirabegron21$10,227
Donepezil Hcl988$9,532
Escitalopram Oxalate466$4,745
Venlafaxine Hcl ErVenlafaxine Hcl252$3,853
Memantine Hcl ErMemantine Hcl54$3,428
Aripiprazole100$3,356
Mirtazapine147$3,265
Quetiapine Fumarate166$2,994
RivastigmineRivastigmine Tartrate53$2,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$844$307,37057 claims
Otsuka America Pharmaceutical, Inc.Rexulti$64,307$118,72089 claims
Corium, LLCAdlarity$12,424$24,77356 claims
Lilly USA, LLCOlanzapine$91,562$38521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →